
Ritopar10 mg
ACI Limited
Ritodrine Hydrochloride is a beta2-adrenergic agonist tocolytic agent.
Ritodrine Hydrochloride is a beta2-adrenergic agonist tocolytic agent.
The use of Ritodrine Hydrochloride for tocolysis has declined substantially in many countries because of its maternal cardiovascular safety profile (including pulmonary edema and arrhythmia risk) and the availability of alternative tocolytics (e.g., calcium channel blockers, oxytocin receptor antagonists) that are generally better tolerated. Ritodrine Hydrochloride is not indicated, and should not be used, for prolonged or maintenance tocolysis, as evidence does not support a meaningful reduction in preterm birth with extended use beyond the acute short-term period.
Ritodrine Hydrochloride must be administered only in a hospital setting under continuous specialist obstetric and cardiac monitoring. Treatment is generally initiated intravenously and, where oral continuation is used, is followed by a limited course of oral therapy; maintenance tocolysis beyond the acute period is not recommended.
| Route | Typical regimen |
|---|---|
| Intravenous infusion | Initiated at a low infusion rate (e.g., approximately 0.05-0.1 mg/minute), increased gradually at intervals (e.g., every 10-20 minutes) according to uterine response and maternal heart rate/blood pressure, up to a maximum recommended infusion rate, until contractions are controlled. Infusion is typically continued for a defined period (commonly around 12-48 hours) after contractions have stopped, then tapered. |
| Oral continuation (where used) | May be started shortly before discontinuing the intravenous infusion, at intervals such as every few hours for the first day, then extended dosing intervals, up to a defined maximum daily dose. Oral maintenance beyond the acute period has not been shown to meaningfully prolong pregnancy and is generally discouraged by current obstetric guidance. |
Exact rates, increments, maximum doses and duration must follow the treating physician's protocol and the approved product label, with continuous maternal cardiac/fluid status and fetal heart rate monitoring throughout intravenous administration of Ritodrine Hydrochloride.
Adverse effects of Ritodrine Hydrochloride are largely an extension of its beta-adrenergic activity and are common, particularly with intravenous administration.
Ritodrine Hydrochloride is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.